TG Therapeutics
NAS:TGTX
Biotechnology
—
SMALL cap
(—)
—
since start of 2022
—
About
BiotechnologyFounded 1993
TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. It also involves developing TG-1101 and TGR-1202 therapies targeting hematological malignancies. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY.
Headquarters
Executives
Name | Title | Gender |
H. Laurence Shaw, MD | Founder | Male |
Michael Sean Weiss | Executive Chairman, President & CEO | Male |
Jenna A. Bosco | Vice President-Investor Relations | Female |
Sean A. Power, CPA | Chief Financial Officer, Secretary & Treasurer | Male |
Robert Niecestro, PhD | Executive Vice President-Clinical & Regulatory | Male |
Mindful Investing Summary
TG Therapeutics - Competitors and Related Companies
How TG Therapeutics stacks up to its peers in theBiotechnology industry or with competing business segments.
TG Therapeutics
NAS:TGTX
Biotechnology
—
SMALL cap
(—)
—
since start of 2022
—
ImmunoGen
NAS:IMGN
Biotechnology
—
SMALL cap
(—)
—
since start of 2022
—
Dr. Reddy's Laboratories
BOM:500124-IN
Pharmaceuticals: Generic
—
MID cap
(—)
—
since start of 2022
—
Histogenics
NAS:HSGX
Biotechnology
—
MICRO cap
(—)
—
since start of 2022
—
Navidea Biopharmaceuticals
ASE:NAVB
Biotechnology
—
MICRO cap
(—)
—
since start of 2022
—